APVO Aptevo Therapeutics Inc.: institutional ownership and insider trading
11 funds reported holding $383K of Aptevo Therapeutics Inc. in their latest 13F filings; in Q2 2026 funds net sold $14.6K, with 1 new positions and 0 funds selling out; over the last 12 months insiders bought $20.1K and sold $0 on the open market.
APVO revenue and earnings
- Quarter ended Jun 30, 2026: revenue n/a, net income −$6.36M, EPS -5.31
- Quarter ended Mar 31, 2026: revenue n/a, net income −$6.70M, EPS -6.41
- Quarter ended Dec 31, 2025: revenue n/a, net income −$5.81M, EPS 1648.06
- Quarter ended Sep 30, 2025: revenue n/a, net income −$7.55M, EPS -2.23
Largest institutional holders of APVO
- VANGUARD GROUP INC — $159K
- GSA CAPITAL PARTNERS LLP — $96.0K
- VANGUARD CAPITAL MANAGEMENT LLC — $56.4K
- GEODE CAPITAL MANAGEMENT, LLC — $48.0K
- VANGUARD FIDUCIARY TRUST CO — $18.4K
- UBS Group AG (UBS) — $3.24K
- OSAIC HOLDINGS, INC. — $1.60K
- SBI Securities Co., Ltd. — $191
- BARCLAYS PLC (BCS, BCLYF) — $138
- CWM, LLC — $21
Recent APVO insider trades
- Nov 10, 2025: Grant Grady III bought 13,513 shares ($20.1K)
5%+ owners
- NIOWAVE, INC.: 12.2% (Schedule 13G, filed Jun 22, 2026)
- CVI Investments, Inc.: 6.3% (Schedule 13G/A, filed Aug 14, 2026)
Who owns the most APVO stock?
The largest institutional holders of Aptevo Therapeutics Inc. in the latest 13F filings are VANGUARD GROUP INC ($159K), GSA CAPITAL PARTNERS LLP ($96.0K), VANGUARD CAPITAL MANAGEMENT LLC ($56.4K).
Are insiders buying or selling APVO?
Over the last 12 months insiders bought $20.1K and sold $0 of Aptevo Therapeutics Inc. stock on the open market (SEC Form 4).